United States · Biotechnology startup
United States · Alumis
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Funding reportedLast round: Series C
What company datasets say Alumis raised
Funding, as reported
Reported in all$529Min dollars
Rounds3
Last roundSeries C
Last round dateMar 2024
Investors listed12
SEC Form D$240M sold, 4 filings, last Jul 2024
Founders and team
From Alumis's own website: 7 on the team.
- Martin BablerPresident and CEO, Chairman of the Board
- Jack DanilkowiczChief Commercial Officer
- John SchroerChief Financial Officer
- Mark BradleyChief Development Officer
- Roy HardimanChief Business and Strategy Officer
- Sanam PangaliChief Legal Officer and Corporate Secretary
- Grace HaltehSVP, Head of Quality and Regulatory
On 3 portfolio pages
Investors who name them
Each firm lists Alumis on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Alumis in front of investors. Or tell us what we have wrong.